-+ 0.00%
-+ 0.00%
-+ 0.00%

Invivyd And SPEAR Study Group Plan To Initiate Phase 2 Clinical Trial Evaluating Monoclonal Antibody VYD2311 In Individuals With Long COVID Or COVID Vaccine Injury

Benzinga·01/20/2026 12:10:11
Listen to the news
  • Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injury
  • Participants to include people with Long COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people including those who have demonstrated persistence of vaccine-delivered spike protein
  • Design includes multiple highly active antibody doses administered over the long term to assess the safety and potential clinical benefit of VYD2311 treatment, versus placebo
  • Millions of individuals continue to live with persistent and debilitating symptoms of Long COVID, underscoring the significant unmet need for development of effective treatment options

NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 in individuals with Long COVID or COVID vaccine injury.